Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
NVNovo Nordisk A/S logo

Novo Nordisk A/S (NVO)

New York Stock Exchange · Currency in USD
$39.05 ▼ -0.38 (-0.96%)
At close: Oct 23, 4:00 PM ET. Market closed.
$39.01 ▼ -0.04 (-0.10%)
After hours: Oct 23, 7:57 PM ET

Summary

Previous Close
$39.43
Open
$39.21
Day's Range
$38.75 – $39.29
52 Week Range
$35.12 – $64.16
Volume
9,120,693
Avg. Volume
12,163,994
Market Cap
$173.99B
Beta (5Y Monthly)
0.35
PE Ratio (TTM)
9.92
EPS (TTM)
$26.30
Earnings Date
Nov 4, 2026
Forward Dividend & Yield
$1.16 (2.97%)
Ex-Dividend Date
Aug 17, 2026
1y Target Est
$42.33

Profile: Novo Nordisk A/S

Sector
Healthcare
Industry
Drug Manufacturers - General
Full-time employees
68,794
CEO
Maziar Mike Doustdar

Novo Nordisk A/S is a global pharmaceutical firm dedicated to the investigation, creation, manufacturing, and distribution of medicinal products across a vast international footprint. Its market presence extends throughout Europe, the Middle East, Africa, various parts of Asia (including Mainland China, Hong Kong, and Taiwan), and North America. The company's operations are structured into two principal business units: Diabetes and Obesity Care, and Rare Disease.

Earnings

Next report: Wed, Nov 4, 2026
EPS estimate $0.73 · Revenue est. $11.11B
DateEst.Actual
Aug 5, 2026$0.82$0.96Beat
May 6, 2026$0.87$1.04Beat
Feb 3, 2026$0.90$1.00Beat
Nov 5, 2025$0.77$1.02Beat
Aug 6, 2025$0.93$0.97Beat
May 7, 2025$0.92$0.92Beat

Analyst view

Consensus price target
$42.33 ▲ +8.4%
Range $40.00 – $47.00
Rating: Buy
Buy 59% · Hold 33% · Sell 8%

Get free alerts on NVO and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.